Human tumor cells grown in fetal calf serum and human serum: Influences on the tests for lymphocyte cytotoxicity, serum blocking and serum arming effects

Peripheral blood lymphoid cells (PBL) from cancer patients and normal donors were tested against three melanoma cell lines grown in either 10% fetal calf serum (FCS) or 2.5‐5% human AB serum in order to determine if the heterologous membrane (HM) antigen or other FCS antigens acquired from the bovine serum supplement could influence lymphoid cell‐mediated cytotoxicity in vitro. FCS‐grown melanoma cells were more susceptible than the AB serumgrown subline to lymphocyte cytotoxic effects. Arming effects by autologous sera on normal donor lymphocytes and to a lesser extent on lymphocytes of cancer patients were more pronounced on the FCS‐grown M12 melanoma cells. This effect was abrogated when the cells were grown in human AB serum for at least 8 weeks. The non‐HM tumor‐associated antigen remained at the same original low level. Blocking effects were more evident on the AB‐grown M14 melanoma line. These data suggest that the FCS antigens on the cell surface may have been responsible for the augmented PBL cytotoxicity. The anti‐FCS antibody present in normal and cancer patients' blood induced an antibody‐dependent cellular cytotoxicity (ADCC). Elimination of arming activity against HM or other FCS antigens from AB‐grown cells may have made the serum blocking factors more apparent. However, cytotoxicity against tumor cells by PBL from normal donors was still apparent even on the human serum‐grown cells, suggesting that a different antigen‐antibody system was also responsible for this “non‐specific” activity.